case_images: PMC5904798_01
case_images: Abdominal CT scan at diagnosis.
case_images: CRIONM2018-4256365.001.jpg
case_images: PMC5904798_01_CRIONM2018-4256365.001.jpg
case_images: fig1
case_images: He was seen by his primary care physician who requested a CT scan of the abdomen that showed a large hepatic mass measuring 34 cm by 26 cm, replacing the majority of the liver without retroperitoneal or mesenteric lymphadenopathy (Figure 1).
case_images: CT scan 24 months after the treatment.
case_images: CRIONM2018-4256365.002.jpg
case_images: PMC5904798_01_CRIONM2018-4256365.002.jpg
case_images: fig2
case_images: CT scan of the abdomen after 4 cycles of nab-paclitaxel revealed shrinkage of the hepatic lesion to 24 x 15 cm in maximum diameter (approximately 7% decrease in the largest lesion per RECIST criteria) (Figure 2).
case_images: Liver biopsy (H&E).
case_images: CRIONM2018-4256365.003.jpg
case_images: PMC5904798_01_CRIONM2018-4256365.003.jpg
case_images: fig3
case_images: Our patient with this metastatic uveal melanoma with extensive liver metastases with GNQ-209P mutation on the tissue biopsy (Figures 3 and 4) and undetectable mutations on the peripheral blood molecular profiling in serial follow-up samples suggests marked response to nab-paclitaxel.
case_images: Liver biopsy (MART).
case_images: CRIONM2018-4256365.004.jpg
case_images: PMC5904798_01_CRIONM2018-4256365.004.jpg
case_images: fig4
case_images: Our patient with this metastatic uveal melanoma with extensive liver metastases with GNQ-209P mutation on the tissue biopsy (Figures 3 and 4) and undetectable mutations on the peripheral blood molecular profiling in serial follow-up samples suggests marked response to nab-paclitaxel.